One Hour Preoperative Gatifloxacin

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Christopher Ta, Stanford University
ClinicalTrials.gov Identifier:
NCT00350363
First received: July 5, 2006
Last updated: June 5, 2012
Last verified: June 2012
  Purpose

Comparison of 1 day versus 1 hour application of topical Zymar.


Condition Intervention Phase
Ophthalmic Surgery
Drug: Zymar
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: One Hour Preoperative Gatifloxacin

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • bacteria count [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    bacteria count


Enrollment: 60
Study Start Date: January 2007
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Zymar
    zymar qid
    Other Name: gatifloxacin
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ophthalmic surgery

Exclusion Criteria:

  • taken antibiotics, allergic to fluoroquinolones
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00350363

Locations
United States, California
Stanford
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

No publications provided

Responsible Party: Christopher Ta, PI, Stanford University
ClinicalTrials.gov Identifier: NCT00350363     History of Changes
Other Study ID Numbers: 5004
Study First Received: July 5, 2006
Last Updated: June 5, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Gatifloxacin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 27, 2014